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A B S T R A C T
Basal cell carcinoma (BCC) is the most common cutaneous malignancy and the most common human malignancy in
general. Out of all basal cell carcinomas, giant basal cell carcinoma represents less than 1%. Only 10% of all basal cell
carcinomas are located on the trunk and majority is located on the head and neck. We describe a patient with a exophytic
giant basal cell carcinoma of the back size 8.5 ´ 8 ´ 6 cm, infiltrating skin 1.5 cm. Two years after the lesion has occurred,
diagnosis was made by pathohistological analysis. The patent was treated surgically, by excision. Review of the litera-
ture that refers to giant basal cell carcinoma was carried out.
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Introduction
Basal cell carcinoma (BCC) is the most common cuta-
neous malignancy and the most common human malig-
nancy in general. Statistical data for BCC is unknown,
because in spite of all other types of carcinomas, BCC is
not reported to cancer registries. According to American
Cancer Society in the United States, in 2007 there were
800 000–900 000 cases of BCC. Incidence of BCC in
United States is 500–1000 per 100 000. Incidence of BCC
increases at a rate of 3 % per year. In 80–85 % of cases
BCC is most often located on the head and neck, while
only 10 % occurs on the trunk1,2,3.
Giant basal cell carcinoma (GBCC) is defined as a tu-
mor larger than 5 cm in diameter and represents less
than 1 % of all basal cell carcinomas. Majority of GBCCs
are located on the trunk. The size of the tumor depends
on numerous factors and the leading one is neglect.
GBCC tend to extend into extradermal structures such
as muscle, bone and cartilage3–7.
Case Report
A 71-year-old female patient presented with a large
cutaneous tumor on her back. The patient waited two
years before coming to our clinic. The lesion was mostly
asymptomatic. From time to time she felt itching and lit-
tle discomfort. She was certain that the lesion was very
small, size 0.5 cm.
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Fig. 1. Exophytic tumor size 8,5 × 8 × 6 cm.
Her family history was noncontributory. She had ap-
pendectomy, gall-stones, osteoartrits of hip and knee and
mild hypertension.
Physical examination revealed well-marginated, pain-
less, exophytic tumor size 8.5 ´ 8 ´ 6 cm which easily
dripped serum and blood. Surface of the tumor was par-
tially ulcerated, with small necrotic areas. Skin around
the tumor was erythematous. (Figure 1.) There was no
evidence of lymph node involvement.
Chest radiography, ultrasound of the liver, scintigraphy
with technetium Tc 99m MDP and laboratory test were
made preoperatively and were all negative. However,
MSCT scan revealed an expansive tumor measuring 8 ´ 6
cm on the back, paramedial left, on the skin in level with
10th thoracic vertebra. Tumor was well vascularized,
without signs of necrosis (Figure 2).
Excison of the tumor with the surrounding skin mea-
suring 15.5 ´15 ´ 2 cm was made. Excision margins were
1 cm from the macroscopic border of the erythematous
skin (Figure 3).
Pathohistological findings revealed regular epidermis
on the surface of the excised erythematous skin that was
surrounding the tumor. Tumor consists of nests of ati-
pical epitelial basaloid cells with peripherally palisading
cells. Stroma surrounds nests of tumor cells and in some
nests keratinization is presented. Infiltration of skin was
1.5 cm and the surgical margins were negative. Tumor
was completely removed (Figure 4).
Excised skin defect was covered with split thickens
skin graft from the right upper thigh (Figure 5). Three
months after the surgery, wound is healing properly.
Discussion
The etiology of BCC is unknown. However, various
endogenous and exogenous factors, single or joined may
be responsible for the development of BCC. The majority
of BCCs are acquired and develop on the chronically
sun-exposed skin in adults (head and neck), which indi-
cates that UV radiation is one of the main causes. Ultra-
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Fig. 2. MSCT scan revealed an expansive tumor size 7 × 5 cm
on the back, in level with 10th thoracic vertebra.
Fig. 3. Excison of the skin with the tumor on top,
size 15,5 ×15 × 2 cm.
Fig. 4. Pathohistological findings of surgically removed
tumor, hemalaun-eosin staining.
Fig. 5. On the defect of the skin Thiersch’ graft was transplanted.
violet B (UVB) radiation (sunburn spectrum 290–320
nm) is considered to be specially dangerous. UVB radia-
tion damages DNA by causing aberrant covalent bonds,
its repair system and immune system. All that results in
progressive genetic alternation and forming of neopla-
sms. Fair-skinned persons (red or blond hair, freckling,
skin types I and II) are especially at risk. Other exoge-
nous risk factors include sun bed use, PUVA therapy,
chronic systemic exposure to toxic substances such as
polycyclic aromatic amines and inorganic arsenic, immuno-
suppression, radiotherapy, or previous traumas such as
burns. Other risk factors are family history of skin can-
cer, advanced age, male sex, amyloidosis3–5,8.
Basal cell nevus syndrome (Gorlin-Goltz syndrome) is
an autosomal dominant disease that is characterized by
multiple BCCs, cysts in mandibula and long bones, ky-
phoscoliosis, calcification of the falx, ovarian fibromas
and eye abnormalities. Mutation of the gene is located on
chromosome 9q22.3-q31.
Classification for BCC is not generally accepted. The
American Joint Committee on Cancer Classification de-
fined BCCs as following: T1 – tumor sized 2 cm or less in
the greatest diameter, T2 – tumors bigger than 2 cm, but
less than 5 cm, T3 – tumor size 5 cm to more (giant basal
cell carcinoma). As distinguished from the American
Joint Committee on Cancer Classification, some reports
define GBCC as a tumor 10 cm or larger in diameter4,7,9.
GBCC is usually seen in patients over 50 with poor
education (received only elementary school degree) and
often with other health problems (for example, chronic
alcoholism, iron deficiency, depression, impaired immu-
nological function, Alzheimer’s disease, amyloidosis, hu-
man Papillomavirus infection). Location of GBCC is usu-
ally on the less visible area4–6.
One of the main reasons for developing GBCC is ne-
glect. Neglect can be ambiguous: from the patent and/or
from the doctor. Patients neglect is a result of denial,
poor education (received only elementary school degree),
cognitive impairment (Alzheimer’s disease) or they were
simply »too busy«. Many of the patients saw physicians
routinely, but they received unadequate treatment of
small BCCs or physician was not thorough in examining
them4–6.
In the present case we reported a patient that had
several risk factors: old age, poor education (did not re-
ceive elementary school degree) and the location of the
tumor on the back (less visible area). The patient waited
over two years before visiting a doctor. As she reported,
she did not want to disturb her family and family doctor.
She thought it was nothing dangerous. She treated pri-
mary lesion self-initiatively with an antibiotic ointment,
which was not efficient. An unexpected perception of a
close relative detected the tumor. Patient was never ex-
posed to radiation or any kind of immunosuppression.
Frequently GBCC infiltrates extradermal structures
such as muscle, bone and cartilage. Histological charac-
teristics of the tumor are important in developing GBCC.
Some histologic subtypes (micronodular, morpheaform
or metatypical) have been considered to be more aggres-
sive forms of BCC, hereby the size of GBCC is larger.
However, other histologic subtypes can also develop
GBCC3,4,6,7,9,10,12–14.
Spates et. all reported that the first report of meta-
statc BCC was in 1894. Although the occurrence of me-
tastasis by BCC is rare (0,03 %) exceeding tumor size in-
creases the incidence of metastasis. Tumors greater than
3 cm have a 2 % incidence of metastasis; tumors greater
than 5 cm have increased that risk up to 25 %; with more
than 10 cm, this risk increases to 50 %; and when tumor
reaches 25 cm in largest diameter metastasis are almost
certain to be found. Mortality rate of metastatic GBCC is
about 50 % within 8 months and metastasis is almost cer-
tain when tumor size exceeds 100 cm2. Our patient had
tumor size 68 cm2, so the absence of metastasisis is not
surprising. The most common organs affected with meta-
stasis are lung, bone and skin. Mortality is caused due to
deep invasion and destruction of muscle, bone, dura caus-
ing infection and destruction of big blood vessels4,5,12,14,15.
Treatment of GBCC is generally surgical by excision.
In case there is a contraindication for a surgical interven-
tion (e.g. older age, poor surgical candidate due to ongoing
medical condition, recurrent tumors, incomplete excision
with residual positive surgical margins) radiotherapy can
be used. Radiotherapy is often used as a palliative treat-
ment, especially in patients with recurrent disease, but
can also be a definitive treatment. Contraindications to
radiotherapy are xeroderma pigmentosum and Gorlin-
-Goltz syndrome. Patients with metastatic disease are
being treated with systemic chemotherapy with some
success. Different chemotherapeutic agents are being
used, such as fluorouracil in combination with vincri-
stine, bleomycine and prednisone. Recently, cisplatin and
paclitaxel are being used11,16.
Conclusion
BCC is the most common malignancy and should be
treated surgicaly. Nonhistologically controlled technique,
such as cryosurgery, curettage, or electrodesiccation should
not be used, because aggressive histologic subtypes of
BCC have a very high recurrence rate. Definitive diagno-
sis is always made by pathologist. Patents with a giant
basal cell carcinoma have some characteristic attributes:
old age, poor education, neglect, denial and specific loca-
tion (less visible area), as our patient. Better health care
and education, especially in rural sector, could prevent
increase of BCC incidence thereby GBCC. Patients with
GBCC should be diagnosed and treated as early as possi-
ble, with mandatory close follow-up.
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VELIKI BAZOCELULARNI KARCINOM NA LE\IMA: PRIKAZ SLU^AJA I PREGLED LITERATURE
S A @ E T A K
Bazocelularni karcinom je naj~e{}i malignitet ko`e, a i naj~e{}i malignitet u ljudi uop}e. Od svih bazocelularnih
karcinoma, veliki bazocelularni karcinom zauzima < 1%. Samo 10% velikih bazocelularnih karcinoma pojavljuje se na
trupu, a ve}ina je smje{tena na glavi i vratu. Prikazana je bolesnica s velikim egzofiti~nim bazocelularnim karcinomom
na le|ima dimenzija 8,5 ´ 8 ´ 6 cm, koji je infiltrirao ko`u 1,5 cm. Dijagnoza je postavljena patohistolo{kom analizom
dvije godine nakon pojave lezije. Bolesnica je tretirana kirur{ki. Iznijeti su podaci iz literature, koji se odnose na veliki
bazocelularni karcinom.
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